Edwards Sapien 3 heart valve gets FDA approva

Edwards Lifesciences’ (NYSE:EW) Sapien 3 Ultra transcatheter heart valve gets U.S. FDA approval.

The approval applies to transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients who are determined to be at intermediate or greater risk of open-heart surgery.

Edwards rises 0.7% in premarket trading.

Previously: Edwards Lifesciences updates on pipeline; sees 2019 sales of $3.9B – 4.3B; shares up 2% (Dec. 6)

https://seekingalpha.com/news/3419538-edwards-sapien-3-heart-valve-gets-fda-approval